You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations
SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC Topic: NIAProject Summary and Abstract Falls are the leading cause of death due to injuryThis simple motion is so common thatof community dwelling older adultsandof long term care facilities will experience a fall in the coming yearThe risk of falling substantially increases for those having Alzheimer s disease and related dementiasand those with Parkinson s diseaseThe financial burden is significant with f ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure
SBC: ToleRaM NanoTech LLC Topic: NIBIBABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice
SBC: BEAM Diagnostics, Inc. Topic: 270PROJECT SUMMARY Alcohol use disorderAUDcontributes to excessive disabilitymorbidityand mortality in the United StatesAs one of the nation s leading preventable causes of deaththe first line of defense against AUD must be standardized screening provided by the patient s primary care physicianpsychiatristand or counselorStandardized screeninghoweveris simply under performedReform proposals call for ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting the host response to limit infection by intracellular bacterial pathogens
SBC: Blue Ridge Biosciences, LLC Topic: NIAIDAntibiotic development has traditionally focused on drugs that target the pathogen but resistance inevitably developsAn attractive alternative is to develop drugs that target the host response and in particular for facultative obligate intracellular bacterial pathogenswhich rely on the host for disease progressionIntracellular bacterial pathogens manipulate the host cytoskeletal system to their ad ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic CAR-T Cell Processing Device
SBC: GPB Scientific, Inc. Topic: 101ABSTRACT The goal of this Fast Track STTR project is to develop a Deterministic Lateral DisplacementDLDmicrofluidic device that can enrich white blood cellsWBCsfrom a typical leukapheresis unit inhrfor use in manufacturing cancer cellular immunotherapyChimeric antigen receptor T cellCAR Ttherapy has been recommended for FDA approval to treat relapsed or refractory pediatric and young adult patient ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
eCPAT: Advancing public park information and technology resources to diverse audiences for healthy communities
SBC: EnQ LLC Topic: NCIProject Summary Abstract Quality parks provide numerous benefits to individuals and communitiesincluding health cost savings through physical activity and stress reliefincreased tax revenue via augmented property values and attracting businessesand positive social and environmental impacts through outcomes such as civic pride and pollution controlThe Community Park Audit ToolCPATprovides a compreh ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health